# Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

> **NCT04790695** · PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Seribantumab

## Key facts

- **NCT ID:** NCT04790695
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2021-12-22
- **Final completion:** 2021-12-22
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790695, "Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04790695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*